
Name
BBVP-M
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for BBVP-M
Name
Alternate Names
Amethopterin
Antifolan
CL-14377
Folex
Methotrexate Sodium
Mexate
Mexate AQ
Rheumatrex
WR-19039
Abbreviations
MTX
Category
Chemotherapy
Subcategory
Antimetabolite
NSC Number
740
000740
Primary Site
Bladder cancer
Breast
Gestational trophoblastic cancer
lymphoma
Meningeal leukemia
Non-Hodgkin lymphoma
Osteogenic sarcoma
Histology
None
Remarks
FDA approved uses on ALL, breast cancer, choriocarcinoma, head and neck cancer, lymphoma, and osteosarcoma.
Coding
This drug should be coded
Name
Alternate Names
Alti-Prednisone
Alto-Pred
Ancortone
Apo-Prednisone
Colisone
Cortan
Dacortin
Delta-Dome#
Deltasone
Deltra
Fernisone Buffered
Keysone
Liquid Pred
Meticorten
Novo-Prednisone
Orasone
Panasol
Paracort#
Prednicen M
SK-Prednisone
Sterapred DS
Ultracorten
Winpred
Abbreviations
PDN
PRD
PRED
Category
Hormones and hormonal mechanisms
Subcategory
Glucocorticoid
NSC Number
10023
010023
Primary Site
Histology
None
Remarks
Code Prednisone when it is part of a drug regimen.
Do not code Prednisone when it is given to treat symptoms or as a single agent. In most cases when Prednisone is given by itself and not as part of a drug regimen, it does not affect the cancer and would not be coded as treatment.
Do not code Prednisone when it is given to treat symptoms or as a single agent. In most cases when Prednisone is given by itself and not as part of a drug regimen, it does not affect the cancer and would not be coded as treatment.
Coding
Please see remarks for additional information
Name
Alternate Names
Blenoxane
Bleo
Bleo-Cell
Bleo-S
Bleomycin for Injection
Bleomycin sulfate
Oil Bleo
Abbreviations
BLE
BLEO
BLM
Category
Chemotherapy
Subcategory
Antitumor antibiotic
NSC Number
125066
Primary Site
Histology
None
Remarks
Phase III melanoma Anti-tumor antibiotic; Genetronics. FDA approved uses on squamous cell cervical cancer, head & neck cancer, Hodgkin's and non-Hodgkin's lymphoma, nasopharyngeal cancer, carcinoma, and testicular cancer.
Coding
This drug should be coded
Name
Alternate Names
BiCNU
Carmustinea
DTI 015
DTI-015
DTI015
WR 139021
WR-139021
WR139021
Abbreviations
BCNU
Category
Chemotherapy
Subcategory
Alkylating agent
NSC Number
409962
Primary Site
Histology
None
Remarks
Phase I FDA approved uses on brain tumor, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma. Guilford Pharmaceuticals.(nitrosourea) (alkylating agent)
Coding
This drug should be coded
